Intravitreal steroids in the management of macular oedema

Acta Ophthalmologica Scandinavica

Volumn 84, Issue 6, 2006, Pages 722-733

  Sivaprasad, Sobha ^a   McCluskey, Peter ^b   Lightman, Susan ^a  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Fluocinolone acetonide; Macular oedema; Posurdex; Triamcinolone

Indexed keywords

DEXAMETHASONE; FLUOCINOLONE ACETONIDE; GLYCOPROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; LIPOCORTIN; LONG ACTING DRUG; MESSENGER RNA; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PLATELET DERIVED GROWTH FACTOR; POSURDEX; STEROID; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN;

BLOOD RETINA BARRIER; CAPILLARY PERMEABILITY; CATARACT; CLINICAL TRIAL; DIABETIC RETINOPATHY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG USE; ENDOPHTHALMITIS; GENE EXPRESSION REGULATION; GLAUCOMA; HUMAN; HYPOPYON; INTRAOCULAR HYPERTENSION; NERVE DEGENERATION; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; PATHOGENESIS; PRIORITY JOURNAL; RETINA CAPILLARY; RETINA DETACHMENT; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA MACULA CYSTOID EDEMA; RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; RETINITIS PIGMENTOSA; RETINOPATHY; REVIEW; TELANGIECTASIA; VITREOUS HEMORRHAGE;

DEXAMETHASONE; FLUOCINOLONE ACETONIDE; GLUCOCORTICOIDS; HUMANS; INFLAMMATION; INJECTIONS; MACULAR EDEMA, CYSTOID; RETINAL VEIN OCCLUSION; TRIAMCINOLONE ACETONIDE; VITREOUS BODY;

EID: 33750620465     PISSN: 13953907     EISSN: 16000420     Source Type: Journal    
DOI: 10.1111/j.1600-0420.2006.00698.x     Document Type: Review

References (144)

1. Abe T, Hayasaka S, Nagaki Y, Kadoi C, Matsumoto M & Hayasaka Y (1999): Pseudophakic cystoid macular oedema treated with high-dose intravenous methyl prednisolone. J Cataract Refract Surg 25: 1286-1288.
2. Adamis AP, Miller JW, Bernal MT, D'Amico DJ, Folkman J, Yeo TK & Yeo KT (1994): Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118: 445-450.
3. Agrawal S, Agrawal J & Agrawal TP (2005): Management of intractable glaucoma following intravitreal triamcinolone acetonide. Am J Ophthalmol 139: 575-576.
4. Alldredge CD & Garretson BR (2003): Intravitreal triamcinolone for the treatment of idiopathic juxtafoveal telangiectasis. Retina 23: 113-116.
5. Antcliff RJ, Spalton DJ, Stanford MR, Graham EM, Ffytche TJ & Marshall J (2001): Intravitreal triamcinolone for uveitic cystoid macular oedema: An optical coherence tomography study. Ophthalmology 108: 765-772.
6. Antonetti DA, Wolpert EB, DeMaio L, Harhaj NS & Scaduto RC Jr (2000): Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin. J Neurochem 80: 667-677.
7. Arnarsson A & Stefansson E (2000): Laser treatment and the mechanism of oedema reduction in branch retinal vein occlusion. Invest Ophthalmol Vis Sci 41: 877-879.
8. Audren F, Tod M, Massin P et.al. (2004): Pharmacokinetic-pharmacodynamic modelling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular oedema. Invest Ophthalmol Vis Sci 45: 3435-3441.
9. Bakri SJ & Beer PM (2003): The effect of intravitreal triamcinolone acetonide on intraocular pressure. Ophthalmic Surg Lasers Imaging 34: 386-390.
10. Bakri SJ & Beer PM (2004): Intravitreal triamcinolone injection for diabetic macular oedema: A clinical and fluorescein angiographic case series. Can J Ophthalmol 39: 755-760.
11. Bashshur ZF, Ma'luf RN, Allam S, Jurdi FA, Haddad RS & Noureddin BN (2004): Intravitreal triamcinolone for the management of macular oedema due to non-ischaemic central retinal vein occlusion. Arch Ophthalmol 122: 1137-1140.
12. Battaglia Parodi M, Saviano S & Ravalico G (1999): Grid laser treatment in macular branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 237: 1024-1027.
13. Beer PM, Bakri SJ, Singh RJ, Liu W, Peters GB III & Miller M (2003): Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 110: 681-686.
14. Benhamou N, Massin P, Haouchine B, Audren F, Tadayoni R & Gaudric A (2003): Intravitreal triamcinolone for refractory pseudophakic macular oedema. Am J Ophthalmol 135: 246-249.
15. Boscia F, Furino C, Dammacco R, Ferreri P, Sborgia L & Sborgia C (2005): Intravitreal triamcinolone acetonide in refractory pseudophakic cystoid macular oedema: Functional and anatomic results. Eur J Ophthalmol 15: 89-95.
16. Branch Vein Occlusion Study Group (1984): Argon laser photocoagulation for macular oedema in branch vein occlusion. Am J Ophthalmol 98: 271-282.
17. Cardillo JA, Melo LA Jr, Costa RA, Skaf M, Belfort R Jr, Souza-Filho AA, Farah ME & Kuppermann BD (2005): Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular oedema. Ophthalmology 112: 1557-1563.
18. Cekic O, Chang S, Tseng JJ, Akar Y, Barile GR & Schiff WM (2005b): Cataract progression after intravitreal triamcinolone injection. Am J Ophthalmol 139: 993-998.
19. Cekic O, Chang S, Tseng JJ et.al. (2005a): Intravitreal triamcinolone treatment for macular oedema associated with central retinal vein occlusion and hemiretinal vein occlusion. Retina 25: 846-850.
20. Central Retinal Vein Occlusion Study Group (1995): Evaluation of grid pattern photocoagulation for macular oedema in central vein occlusion. Ophthalmology 102: 1425-1433.
21. Central Retinal Vein Occlusion Study Group (1997): Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 115: 486-491.
22. Chan CK, Fan DS, Chan WM, Lai WW, Lee VY & Lam DS (2005): Ocular-hypertensive response and corneal endothelial changes after intravitreal triamcinolone injections in Chinese subjects: A 6-month follow-up study. Eye 19: 625-630.
23. Chen SD, Lochhead J, McDonald B & Patel CK (2004b): Pseudohypopyon after intravitreal triamcinolone injection for the treatment of pseudophakic cystoid macular oedema. Br J Ophthalmol 88: 843-844.
24. Chen SD, Lochhead J, Patel CK & Frith P (2004a): Intravitreal triamcinolone acetonide for ischaemic macular oedema caused by branch retinal vein occlusion. Br J Ophthalmol 88: 154-155.
25. Cheng CK, Berger AS, Pearson PA, Ashton P & Jaffe GJ (1995): Intravitreal sustained-release dexamethasone device in the treatment of experimental uveitis. Invest Ophthalmol Vis Sci 36: 442-453.
26. Chin HS, Park TS, Moon YS & Oh JH (2005): Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and non-vitrectomized eyes. Retina 25: 556-560.
27. Ciardella AP, Klancnik J, Schiff W, Barile G, Langton K & Chang S (2004): Intravitreal triamcinolone for the treatment of refractory diabetic macular oedema with hard exudates: An optical coherence tomography study. Br J Ophthalmol 88: 1131-1136.
28. Ciulla TA, Walker JD, Fong DS & Criswell MH (2004): Corticosteroids in posterior segment disease: An update on new delivery systems and new indications. Curr Opin Ophthalmol 15: 211-220.
29. Cohen T, Nahari D, Cerem LW, Neufeld G & Levi BZ (1996): Interleukin-6 induces the expression of vascular endothelial growth factor. J Biol Chem 271: 736-741.
30. Conway MD, Canakis C, Livir-Rallatos C & Peyman GA (2003): Intravitreal triamcinolone acetonide for refractory chronic pseudophakic cystoid macular oedema. J Cataract Refract Surg 29: 27-33.
31. Cox SN, Hay E & Bird AC (1988): Treatment of chronic macular oedema with acetozolamide. Arch Ophthalmol 106: 1190-1195.
32. Cunha Vaz DJ (1976): The blood-retinal barriers. Doc Ophthalmol 41: 287-327.
33. Das-Bhaumik RG & Jones NP (2005): Low-dose intraocular triamcinolone injection for intractable macular oedema and inflammation in patients with uveitis. Eye Epub ahead of print: (PMID) 160 96656.
34. Detry-Morel M, Escarmelle A & Hermans I (2004): Refractory ocular hypertension secondary to intravitreal injection of triamcinolone acetonide. Bull Soc Belge Ophtalmol 292: 45-51.
35. Driot JY, Novack GD, Rittenhouse KD, Milazzo C & Pearson PA (2004): Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period. J Ocul Pharmacol Ther 20: 269-275.
36. Drolsum L & Haaskjold E (1995): Causes of decreased visual acuity after cataract extraction. J Cataract Refract Surg 21: 59-63.
37. Dugel PU, Rao NA, Ozler S, Ligget PE & Smith RE (1992): Pars plana vitrectomy for intraocular inflammation-related cystoid macular oedema unresponsive to corticosteroids. Ophthalmology 99: 1535-1541.
38. Estafanous MF, Lowder CY & Kaiser PK (2005): Patterns of macular oedema in uveitis patients. Ophthalmology 112: 360.
39. Faber MD, Lam S, Tessler HH, Jennings TJ, Cross A & Ruskin MM (1994): Reduction of macular oedema by acetozolamide in patients with chronic iridocyclitis: A randomized prospective crossover study. Br J Ophthalmol 78: 4-7.
40. Figueroa MS, Torres R & Alvarez MT (2004): Comparative study of vitrectomy with and without vein decompression for branch retinal vein occlusion: A pilot study. Eur J Ophthalmol 14: 40-47.
41. Funatsu H, Yamashita H, Ikeda T, Mimura T, Eguchi S & Hori S (2003): Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular oedema. Ophthalmology 110: 1690-1696.
42. Garcia-Arumi J, Boixadera A, Giralt J, Martinez-Castillo V, Gomez-Ulla F, Corcostegui B & Garcia-Arumi E (2005): Comparison of different techniques for purification of triamcinolone acetonide suspension for intravitreal use. Br J Ophthalmol 89: 1112-1114.
43. Gardner TW, Antonetti DA, Barber AJ, Lieth E & Tarbell JA (1999): The molecular structure and function of the inner blood-retinal barrier. Pennsylvania State Retina Research Group. Doc Ophthalmol 97: 229-237.
44. Gillies MC, Kuzniarz M, Craig J, Ball M, Luo W & Simpson JM (2005): Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. Ophthalmology 112: 139-143.
45. Graham RO & Peyman GA (1974): Intravitreal injection of dexamethasone. Treatment of experimentally induced endophthalmitis. Arch Ophthalmol 92: 149-154.
46. Greenberg PB, Martidis A, Rogers AH, Duker JS & Reichel E (2002): Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Br J Ophthalmol 86: 247-248.
47. Hainsworth DP, Pearson PA, Conklin JD & Ashton P (1996): Sustained release intravitreal dexamethasone. J Ocul Pharmacol Ther 12: 57-63.
48. Hayashi K & Hayashi H (2005): Intravitreal versus retrobulbar injections of triamcinolone for macular oedema associated with branch retinal vein occlusion. Am J Ophthalmol 139: 972-982.
49. Hida T, Chandler D, Arena JE & Machemer R (1986): Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol 101: 190-195.
50. Imasawa M, Ohshiro T, Gotoh T, Imai M & Iijima H (2005): Central serous chorioretinopathy following vitrectomy with intravitreal triamcinolone acetonide for diabetic macular oedema. Acta Ophthalmol Scand 83: 132-133.
51. Ip M, Kahana A & Altaweel M (2003): Treatment of central retinal vein occlusion with triamcinolone acetonide: An optical coherence tomography study. Semin Ophthalmol 18: 67-73.
52. Irvine SR (1953): A newly defined vitreous syndrome following cataract surgery. Am J Ophthalmol 36: 599-619.
53. Ishibashi T, Miki K, Sorgente N, Patterson R & Ryan SJ (1985): Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate. Arch Ophthalmol 103: 708-711.
54. Jaffe GJ, McCallum RM, Branchaud B, Skalak C, Butuner Z & Ashton P (2005): Longterm follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology 112: 1192-1198.
55. Jaffe GJ, Yang CH, Guo H, Denny JP, Lima C & Ashton P (2000): Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest Ophthalmol Vis Sci 41: 3569-3575.
56. Jonas JB, Akkoyun I, Kreissig I & Degenring RF (2005d): Diffuse diabetic macular oedema treated by intravitreal triamcinolone acetonide: a comparative, non-randomized study. Br J Ophthalmol 89: 321-326.
57. Jonas JB, Degenring RF & Kamppeter BA (2004c): Outcome of eyes undergoing trabeculectomy after intravitreal injections of triamcinolone acetonide. J Glaucoma 13: 261.
58. Jonas JB, Degenring RF, Kamppeter BA, Kreissig I & Akkoyun I (2004a): Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular oedema. Am J Ophthalmol 138: 158-160.
59. Jonas JB, Degenring RF, Kreissig I, Akkoyun I & Kamppeter BA (2005a): Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 112: 593-598.
60. Jonas JB, Degenring R, Vossmerbauemer U & Kamppeter B (2005b): Frequency of cataract surgery after intravitreal injection of high-dosage triamcinolone acetonide. Eur J Ophthalmol 15: 462-464.
61. Jonas JB, Harder B & Kamppeter BA (2004b): Inter-eye difference in diabetic macular oedema after unilateral intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 138: 970-977.
62. Jonas JB, Hayler JK, Söfker A & Panda-Jonas S (2001): Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 131: 468-471.
63. Jonas JB & Kamppeter BA (2005): Intravitreal triamcinolone acetonide and central serous chorioretinopathy. Br J Ophthalmol 89: 386-387.
64. Jonas JB, Kreissig I & Degenring RF (2002): Intravitreal triamcinolone acetonide as treatment of macular oedema in central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 240: 782-783.
65. Jonas JB, Kreissig I & Degenring R (2003d): Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 87: 24-27.
66. Jonas JB, Kreissig I & Degenring RF (2003c): Intravitreal triamcinolone acetonide for pseudophakic cystoid macular oedema. Am J Ophthalmol 136: 384-386.
67. Jonas JB, Kreissig I & Degenring RF (2004d): Cataract surgery after intravitreal injection of triamcinolone acetonide. Eye 18: 361-364.
68. Jonas JB, Kreissig I & Degenring R (2005c): Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative and neovascular diseases. Prog Retin Eye Res 24: 587-611.
69. Jonas JB, Kreissig I, Hugger P, Sauder G, Panda-Jonas S & Degenring R (2003a): Intravitreal triamcinolone acetonide for exudative age-related macular degeneration. Br J Ophthalmol 87: 462-466.
70. Jonas JB, Kreissig I, Sofker A & Degenring RF (2003b): Intravitreal injection of triamcinolone for diffuse diabetic macular oedema. Arch Ophthalmol 121: 57-61.
71. Jonas JB & Sofker A (2001): Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular oedema. Am J Ophthalmol 132: 425-427.
72. Karacorlu M (2005): Intravitreal triamcinolone as a primary therapy in diabetic macular oedema. Eye Epub ahead of print: (PMID) 160 9660.
73. Karacorlu M, Mudun B, Ozdemir H, Karacorlu SA & Burumcek E (2004b): Intravitreal triamcinolone acetonide for the treatment of cystoid macular oedema secondary to Behcet disease. Am J Ophthalmol 138: 289-291.
74. Karacorlu M, Ozdemir H & Karacorlu S (2003): Intravitreal triamcinolone acetonide for the treatment of chronic pseudophakic cystoid macular oedema. Acta Ophthalmol Scand 81: 648-652.
75. Karacorlu M, Ozdemir H & Karacorlu S (2004a): Intravitreal triamcinolone acetonide for the treatment of central retinal vein occlusion in young patients. Retina 24: 324-327.
76. Karacorlu M, Ozdemir H, Karacorlu S, Alacali N, Mudun B & Burumcek E (2004c): Intravitreal triamcinolone as a primary therapy in diabetic macular oedema. Eye 19: 382-386.
77. Kok H, Lau C, Maycock N, McCluskey P & Lightman S (2005): Outcome of intravitreal triamcinolone in uveitis. Ophthalmology 112: 1916.
78. Kragballe K (1989):MTopical corticosteroids: mechanisms of action. Acta Derm Venereol (Stockh) 151 (Suppl): 7-10.
79. Krepler K, Ergun E, Sacu S, Richter-Muksch S, Wagner J, Stur M & Wedrich A (2005b): Intravitreal triamcinolone acetonide in patients with macular oedema due to central retinal vein occlusion. Acta Ophthalmol Scand 83: 71-75.
80. Krepler K, Wagner J, Sacu S & Wedrich A (2005a): The effect of intravitreal triamcinolone on diabetic macular oedema. Graefes Arch Clin Exp Ophthalmol 243: 478-481.
81. Kupperman B, Dugel P, Williams G, Weinberg D, Batoosingh A, Chou C & Haller J (2005): A comparison of applicator versus incisional placement of the dexamethasone sustained release drug delivery system. Paper presented at the American Academy of Ophthalmology, Chicago, Illinois, USA, 17 October 2005.
82. Kwak HW & D'Amico DJ (1992): Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch Ophthalmol 110: 259-266.
83. Lahey JM, Kearney JJ & Cheung MC (2004): Sequential treatment of central retinal vein occlusion with intravitreal tissue plasminogen activator and intravitreal triamcinolone. Br J Ophthalmol 88: 1100-1101.
84. Lam DS, Chan CK, Tang EW, Li KK, Fan DS & Chan WM (2004): Intravitreal triamcinolone for diabetic macular oedema in Chinese patients: 6-month prospective longitudinal pilot study. Clin Exp Ophthalmol 32: 569-572.
85. Larsson J, Zhu M, Sutter F & Gillies MC (2005): Relation between reduction of foveal thickness and visual acuity in diabetic macular oedema treated with intravitreal triamcinolone. Am J Ophthalmol 139: 802-806.
86. Lee CM & Olk RJ (1991): Modified grid laser photocoagulation for diffuse diabetic macular oedema. Longterm visual results. Ophthalmology 98: 1594-1602.
87. Leung DW, Cachianes G, Kuang WJ, Goeddel DV & Ferrara N (1989): Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306-1309.
88. Lightman S (1991): Use of steroids and immunosuppressive drugs in the management of uveitis. Lancet 338: 1501-1504.
89. Maar N, Luksch A, Graebe A et.al. (2004): Effect of laser photocoagulation on the retinal vessel diameter in branch and macular vein occlusion. Arch Ophthalmol 122: 987-991.
90. Markomichelakis NN, Halkiadakis I, Pantelia E, Peponis V, Patelis A, Theodossiadis P & Theodossiadis G (2004): Patterns of macular oedema in patients with uveitis: Qualitative and quantitative assessment using optical coherence tomography. Ophthalmology 111: 946-953.
91. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E & Baumal C (2002): Intravitreal triamcinolone for refractory diabetic macular oedema. Ophthalmology 109: 920-927.
92. Martidis A, Duker JS & Puliafito CA (2001): Intravitreal triamcinolone for refractory cystoid macular oedema secondary to birdshot retinochoroidopathy. Arch Ophthalmol 119: 1380-1383.
93. Martinez JA (2003): Intravitreal triamcinolone acetonide for bilateral acquired parafoveal telangiectasis. Arch Ophthalmol 121: 1658-1659.
94. Maruo N, Morita I, Shirao M & Murota S (1992): IL-6 increases endothelial permeability in vitro. Endocrinology 131: 710-714.
95. Massin P, Audren F, Haouchine B, Erginay A, Bergmann JF, Benosman R, Caulin C & Gaudric A (2004): Intravitreal triamcinolone acetonide for diabetic diffuse macular oedema: Preliminary results of a prospective controlled trial. Ophthalmology 111: 218-224.
96. Micelli Ferrari T, Sborgia L, Furino C, Cardascia N, Ferreri P, Besozzi G & Sborgia C (2004): Intravitreal triamcinolone acetonide: valuation of retinal thickness changes measured by optical coherence tomography in diffuse diabetic macular oedema. Eur J Ophthalmol 14: 321-324.
97. Morita Y, Ohtori A, Kimura M & Tojo K (1998): Intravitreous delivery of dexamethasone sodium m-sulfobenzoate from poly (DL-lactic acid) implants. Biol Pharm Bull 21: 188-190.
98. Moshfeghi DM, Kaiser PK, Scott IU et.al. (2003): Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol 136: 791-796.
99. Moshfeghi AA, Scott IU, Flynn HW Jr & Puliafito CA (2004): Pseudohypopyon after intravitreal triamcinolone acetonide injection for cystoid macular oedema. Am J Ophthalmol 138: 489-492.
100. Nauck M, Karakiulakis G, Perruchoud A, Papakonstantinou E & Roth M (1998a): Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Euro J Pharmacol 341: 309-315.
101. Nauck M, Roth M, Tamm M, Eickelberg O, Wieland H, Stulz P & Perruchoud AP (1998b): Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids. Am J Resp Cell Mol Biol 16: 398-406.
102. Negi AK, Vernon SA, Lim CS & Owen-Armstrong K (2005): Intravitreal triamcinolone improves vision in eyes with chronic diabetic macular oedema refractory to laser photocoagulation. Eye 19: 747-751.
103. Nelson ML, Tennant MT, Sivalingam A, Regillo CD, Belmont JB & Martidis A (2003): Infectious and presumed non-infectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina 23: 686-691.
104. Noma H, Funatsu H, Yamasaki M et.al. (2005): Pathogenesis of macular oedema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol 140: 256-261.
105. Olk RJ (1990): Argon green (514 nm) versus krypton red (647 nm) modified grid laser photocoagulation for diffuse diabetic macular oedema. Ophthalmology 97: 1101-1112.
106. Otani T, Kishi S & Maruyama Y (1999): Patterns of diabetic macular oedema with optical coherence tomography. Am J Ophthalmol 127: 688-693.
107. Ozdemir H, Karacorlu M & Karacorlu S (2005a): Intravitreal triamcinolone acetonide for treatment of cystoid macular oedema in patients with retinitis pigmentosa. Acta Ophthalmol Scand 83 (2): 248-51.
108. Ozdemir H, Karacorlu M & Karacorlu SA (2005b): Regression of serous macular detachment after intravitreal triamcinolone acetonide in patients with diabetic macular oedema. Am J Ophthalmol 140: 251-255.
109. Ozkiris A & Erkilic K (2005): Complications of intravitreal injection of triamcinolone acetonide. Can J Ophthalmol 40: 63-68.
110. Ozkiris A, Evereklioglu C, Erkilic K & Ilhan O (2005): The efficacy of intravitreal triamcinolone acetonide on macular oedema in branch retinal vein occlusion. Eur J Ophthalmol 15: 96-101.
111. Ozkiris A, Evereklioglu C, Erkilic K, Tamcelik N & Mirza E (2004): Intravitreal triamcinolone acetonide injection as primary treatment for diabetic macular oedema. Eur J Ophthalmol 14: 543-549.
112. Park CH, Jaffe GJ & Fekrat S (2003): Intravitreal triamcinolone acetonide in eyes with cystoid macular oedema associated with central retinal vein occlusion. Am J Ophthalmol 136: 419-425.
113. Peyman P & HerbstTR (1974): Bacterial endophthalmitis: treatment with intraocular gentamycin and dexamethasone. Arch Ophthalmol 91: 416-418.
114. Riordan-Eva P & Lightman S (1994): Orbital floor steroid injections in the treatment of uveitis. Eye 8: 66-69.
115. Rodriguez-Coleman H, Yuan P, Kim H, Gravlin L, Srivastava S, Csaky KG & Robinson MR (2004): Intravitreal injection of triamcinolone for diffuse macular oedema. Arch Ophthalmol 112: 1085-1086.
116. Roth DB, Chieh J, Spirn MJ, Green SN, Yarian DL & Chaudhry NA (2003): Non-infectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol 121: 1279-1282.
117. Rothova A, Suttorp-van Schulten MS, Frits Treffers W & Kijlstra A (1996): Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 80: 6.
118. Sallum JM, Farah ME, Saraiva VS (2003): Treatment of cystoid macular oedema related to retinitis pigmentosa with intravitreal triamcinolone acetonide: Case report. Adv Exp Med Biol 533: 79-81.
119. Saraiva VS, Sallum JM & Farah ME (2003): Treatment of cystoid macular oedema related to retinitis pigmentosa with intravitreal triamcinolone acetonide. Ophthalmic Surg Lasers Imaging 34: 398-400.
120. Shah A & Branley M (2005): Use of intravitreal triamcinolone in the management of birdshot retinochoroidopathy associated with cystoid macular oedema: A case study over a 3-year period. Clin Exp Ophthalmol 33: 442-444.
121. Shah GK, Sharma S, Fineman MS, Federman J, Brown MM & Brown GC (2000): Arteriovenous adventitial sheathotomy for the treatment of macular oedema associated with branch retinal vein occlusion. Am J Ophthalmol 129: 104-106.
122. Sharma MC, Lai WW & Shapiro MJ (2004): Pseudohypopyon following intravitreal triamcinolone acetonide injection. Cornea 23: 398-399.
123. Smith RE, Godfrey WA & Kimura SJ (1976): Complications of chronic cyclitis. Am J Ophthalmol 82: 277-282.
124. Smithen LM & Spaide RF (2004): Photodynamic therapy and intravitreal triamcinolone for a subretinal neovascularization in bilateral idiopathic juxtafoveal telangiectasis. Am J Ophthalmol 138: 884-885.
125. Sorensen TL, Haamann P, Villumsen J & Larsen M (2005): Intravitreal triamcinolone for macular oedema: Efficacy in relation to aetiology. Acta Ophthalmol Scand 83: 67-70.
126. Spada C, Lin T, Jackson B et.al. (2005): Posurdex inhibits retinal vasculopathy and neuropathy induced by intravitreal vascular endothelial growth factor (VEGF) in monkeys. Paper presented at the Association for Research into Vision and Ophthalmology, Florida, USA, 4 May 2005.
127. Spandau UH, Derse M, Schmitz-Valckenberg P, Papoulis C & Jonas JB (2005): Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular oedema. Br J Ophthalmol 89: 999-1003.
128. Sutter FK & Gillies MC (2003): Pseudoendophthalmitis after intravitreal injection of triamcinolone. Br J Ophthalmol 87: 972-974.
129. Sutter FK, Simpson JM & Gillies MC (2004): Intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment: 3-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology 111: 2044-2049.
130. Suttorp-Schulten MSA, Feron E, Postema F, Kijlstra A & Rothova A (1995): Macular grid photocoagulation in uveitis. Br J Ophthalmol 79: 821-824.
131. Tamura H, Miyamoto K, Kiryu J, Miyahara S, Katsuta H, Hirose F, Musashi K & Yoshimura N (2005): Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci 46: 1440-1444.
132. Tanner V, Kanski JJ & Frith PA (1998): Posterior sub-Tenon's triamcinolone injections in the treatment of uveitis. Eye 12: 679-685.
133. Tano Y, Chandler D & Machemer R (1980): Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 90: 810-816.
134. Tranos PG, Wickremasinghe SS, Stangos NT, Topouzis F, Tsinopoulos I & Pavesio CE (2004): Macular oedema. Surv Ophthalmol 49: 470-490.
135. Vane J & Botting R (1987): Inflammation and the mechanism of action of anti-inflammatory drugs. FASEB J 1: 89-96.
136. Westfall AC, Osborn A, Kuhl D, Benz MS, Mieler WF & Holz ER (2005): Acute endophthalmitis incidence: Intravitreal triamcinolone. Arch Ophthalmol 123: 1075-1077.
137. Whitcup SM, Csaky KG, Podgor MJ, Chew EY, Perry CH & Nussenblatt RB (1996): A randomized, masked, cross-over trial of acetazolamide for cystoid macular oedema in patients with uveitis. Ophthalmology 103: 1054-1063.
138. Williams GA, Kupperman BD, Blumenkranz MS, Haller JA, Weinberg DV & Whitcup SM (2005): Treatment of inflammatory oedema with a dexamethasone posterior segment drug delivery system (Posurdex). Paper presented at the Association for Research into Vision and Ophthalmology, Florida, USA, 5 May 2005).
139. Williamson TH & O'Donnell A (2005): Intravitreal triamcinolone acetonide for cystoid macular oedema in non-ischaemic central retinal vein occlusion. Am J Ophthalmol 139: 860-866.
140. Xu F & Severinghaus JW (1998): Expression and response to hypoxia of vascular endothelial growth factor (VEGF) in rat and rabbit tissues. Adv Exp Med Biol 454: 311-317.
141. Yamaji H, Shiraga F, Tsuchida Y, Yamamoto Y & Ohtsuki H (2004): Evaluation of arteriovenous crossing sheathotomy for branch retinal vein occlusion by fluorescein videoangiography and image analysis. Am J Ophthalmol 137: 834-841.
142. Yepremyan M, Wertz FD, Tivnan T, Eversman L & Marx JL (2005): Early treatment of cystoid macular oedema secondary to branch retinal vein occlusion with intravitreal triamcinolone acetonide. Ophthalmic Surg Lasers Imaging 36: 30-36.
143. Young S, Larkin G, Branley M & Lightman S (2001): Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Experiment Ophthalmol 29: 2-6.
144. Zaidi FH, Gair EJ & Gregory-Evans K (2004): Criteria for improving visual acuity in ischaemic branch retinal vein occlusion using argon laser. Eye 18: 316-318.